Monoclonal antibodies for the treatment of COVID‐19 in a patient with high‐risk acute leukaemia

Saultier, Paul; Ninove, Laëtitia; Szepetowski, Sarah; Veneziano, Mathilde; Visentin, Sandrine; Barlogis, Vincent; Villarroel, Paola Mariela Saba; Amroun, Abdennour; Loosveld, Marie; Lamballerie, Xavier de; Chambost, Hérvè

doi:10.1111/bjh.17756

Cited by 11 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,8 In literature, robust data on NmAbs effectivity in COVID-19 positive hematological patients are still lacking. 9,10 As a result, we resolved to analyze results of what at the time was dominantly the largest cohort of COVID-19 immunocompromized hematology patients treated with NmAbs-bamlanivimab or casirivimab/imdevimab.…”

Section: Introductionmentioning

confidence: 99%

Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience

Weinbergerová

Demel

Víšek

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) -bamlanivimab (72%) and casirivimab/imdevimab (28%) -efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively.

show abstract

Section: Introductionmentioning

confidence: 99%

Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience

Weinbergerová

Demel

Víšek

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Another important finding of our study was that an early use of mAbs was associated with lower rate of critical COVID‐19 11 (21% versus 54% in patients treated and not with mAbs, respectively) even after adjustment for potential confounders such as age or comorbidities. Although clinical trials with mAbs have demonstrated their efficacy in the population with high risk to develop severe disease, including immunocompromised patients, studies focusing on outcome of hematologic cancer patients are currently limited and mainly consist of case reports [ 12 , 13 , 14 ]. In a single‐center retrospective study, 38 patients with HM received bamlanivimab or casirivimab/imdevimab, and four of them (11%, all who received bamlanivimab monotherapy) needed hospitalization, two of them (5%) developed severe COVID‐19, and one died [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients

Bussini

Testi

Tazza

et al. 2022

eJHaem

View full text Add to dashboard Cite

Efficacy of early treatment with anti‐SARS‐CoV‐2 spike protein monoclonal antibodies (mAbs) for nosocomial SARS‐CoV‐2 infection in hematologic patients is unknown. Retrospective, cohort study conducted in four Italian teaching hospitals. We included adult patients with hematologic malignancies and hospital‐acquired SARS‐CoV‐2 infection diagnosed between November 2020 and December 2021. The principal exposure variable was administration of mAbs. The primary endpoint was clinical failure dea composite outcome of mortality and/or invasive and noninvasive ventilation within 90 days from infection onset. We included 52 patients with hospital‐acquired SARS‐CoV‐2 infection. Males were 29 (60%), median age was 62 (interquartile range [IQR] 48–70). Forty‐five (86%) patients were on chemotherapy or had received chemotherapy within 30 days. MAbs were administered in 19/52 (36%) patients. Clinical failure occurred in 22 (42%) patients; 21% (4/19) in mAbs group versus 54% (18/33) in non‐mAbs group ( p = 0.03). Other predictors of clinical failure were older age (median [IQR] 69 [61–72] versus 58 [46–66], p = 0.001), and higher Charlson comorbidity index (median [IQR], 5 [3.25‐5] versus 3 [2–5], p = 0.002). At multivariable Cox regression model, mAbs were independently associated with a significantly lower rate of clinical failure (HR 0.11, 95% CI 0.01–0.85, p = 0.01), after adjusting for confounders. In conclusion, mAbs are promising for early treatment of hematologic patients with healthcare‐related SARS‐CoV‐2 infection.

show abstract

“…However, there are points that pertain to the unique characteristics of these patients that may ought to be taken into account, including current and cumulative glucocorticoid doses, presence of hypogammaglobulinemia, perceived degree of immune suppression due to the illness or its therapy, cytopenic status due to the underlying condition or the risk of cytopenia from certain COVID-19 medical treatments (e.g., Remdesivir, Molnupiravir). Various therapies or combinations have been successfully used among hematologic patients [157][158][159][160]. In a series of 313 patients with hematologic malignancies from Israel, Remdesivir administration was associated with decreased mortality [65].…”

Section: Medical Therapy Against Covid-19 Among Individuals With Hema...mentioning

confidence: 99%

The Challenges of COVID-19 with Obesity-Related Cancers

2023

View full text Add to dashboard Cite

show abstract

Monoclonal antibodies for the treatment of COVID‐19 in a patient with high‐risk acute leukaemia

Cited by 11 publications

References 6 publications

Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience

Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience

Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients

The Challenges of COVID-19 with Obesity-Related Cancers

Contact Info

Product

Resources

About